A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With B-Lineage Acute Lymphoblastic Leukemia and Highly Aggressive Lymphomas

Trial Profile

A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With B-Lineage Acute Lymphoblastic Leukemia and Highly Aggressive Lymphomas

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Jul 2017

At a glance

  • Drugs Denintuzumab mafodotin (Primary)
  • Indications Acute lymphoblastic leukaemia; B cell lymphoma; Burkitt's lymphoma; Leukaemia; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; First in man
  • Sponsors Seattle Genetics
  • Most Recent Events

    • 29 Jun 2017 Status changed from active, no longer recruiting to completed.
    • 04 Mar 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 28 Jan 2016 Planned End Date changed from 1 Jun 2016 to 1 May 2019 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top